[go: up one dir, main page]

RU2021119487A - Combination drug with antiviral effect for the prevention of infection with SARS-CoV-2 - Google Patents

Combination drug with antiviral effect for the prevention of infection with SARS-CoV-2 Download PDF

Info

Publication number
RU2021119487A
RU2021119487A RU2021119487A RU2021119487A RU2021119487A RU 2021119487 A RU2021119487 A RU 2021119487A RU 2021119487 A RU2021119487 A RU 2021119487A RU 2021119487 A RU2021119487 A RU 2021119487A RU 2021119487 A RU2021119487 A RU 2021119487A
Authority
RU
Russia
Prior art keywords
cov
sars
prevention
infection
combination drug
Prior art date
Application number
RU2021119487A
Other languages
Russian (ru)
Inventor
Шахноз Садыковна Азимова
Талат Саатович Саатов
Баходир Равилович Зайнутдинов
Ойбек Норбой Аширов
Собирджан Анарматович Сасмаков
Елена Лысова
Артем Александрович Махнев
Мукаддас Рустамовна Умарова
Умида Бахриддин Кизи Хамидова
Галина Александровна Пиякина
Джалолиддин Мирджамилович Абдурахманов
Шухрат Шавкатович Хасанов
Фарход Бакир Эшбоев
Original Assignee
Мусаханова Ойгуль Мирзаюсуфовна
Filing date
Publication date
Application filed by Мусаханова Ойгуль Мирзаюсуфовна filed Critical Мусаханова Ойгуль Мирзаюсуфовна
Priority to PCT/RU2022/000207 priority Critical patent/WO2023277730A1/en
Priority to CN202280047238.2A priority patent/CN117651550A/en
Publication of RU2021119487A publication Critical patent/RU2021119487A/en

Links

Claims (4)

1. Комбинированные лекарственные средства для профилактики (лечения) коронавирусной инфекции, вызываемой SARS-CoV-2, содержащие эффективное количество молекул РНКазы в липосомах.1. Combined medicinal products for the prevention (treatment) of coronavirus infection caused by SARS-CoV-2, containing an effective amount of RNase molecules in liposomes. 2. Комбинированные лекарственные средства для профилактики (лечения) коронавирусной инфекции, вызываемой SARS-CoV-2, содержащие эффективное количество молекул РНКазы и никлозамида в липосомах.2. Combined medicinal products for the prevention (treatment) of coronavirus infection caused by SARS-CoV-2, containing an effective amount of RNase and niclosamide molecules in liposomes. 3. Комбинированные лекарственные средства по пп. 1 и 2, предназначенные для интраназального или ингаляционного введения.3. Combined drugs according to paragraphs. 1 and 2 intended for intranasal or inhalation administration. 4. Способ профилактики или лечения SARS-CoV-2 инфекции, в котором комбинированные лекарственные средства по пп. 1 и 2 вводятся одновременно, отдельно или последовательно с другими терапевтическими средствами.4. A method for the prevention or treatment of SARS-CoV-2 infection, in which the combined drugs according to paragraphs. 1 and 2 are administered simultaneously, separately or sequentially with other therapeutic agents.
RU2021119487A 2021-07-02 2021-07-02 Combination drug with antiviral effect for the prevention of infection with SARS-CoV-2 RU2021119487A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/RU2022/000207 WO2023277730A1 (en) 2021-07-02 2022-06-30 Drug for the prophylaxis of sars-cov-2 infection
CN202280047238.2A CN117651550A (en) 2021-07-02 2022-06-30 Drugs used to prevent SARS-CoV-2 infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2022101386A Division RU2022101386A (en) 2022-01-21 The use of a drug having an antiviral effect for the prevention or treatment of SARS-CoV-2 coronavirus infection (variants) and a method for the prevention or treatment of SARS-CoV-2 (infection)

Publications (1)

Publication Number Publication Date
RU2021119487A true RU2021119487A (en) 2023-01-02

Family

ID=

Similar Documents

Publication Publication Date Title
EA200802012A1 (en) PHARMACEUTICAL PREPARATIONS IN THE FORM OF SOLUTION FOR DOSING INHALERS UNDER PRESSURE
ES2202265T3 (en) MEDICINAL AEROSOL IN THE TREATMENT OR PREVENTION OF PAIN.
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
EA201590166A1 (en) COMBINED THERAPY FOR THE TREATMENT OF SCATTERED SCLEROSIS
UA107578C2 (en) COMBINED DIABETES THERAPY
HRP20140592T1 (en) IMPROVED MEDICINAL PRODUCTS CONTAINING BUPRENORPHINE AND NALTREXONE
HRP20192189T1 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
Shen et al. The potential of artemisinins as anti-obesity agents via modulating the immune system
ES2369547T8 (en) PROCEDURE FOR THE TREATMENT OF HUMAN DISEASES ASSOCIATED WITH A HIGH CONTENT OF DEOXIRRIBONUCLEIC ACID IN THE EXTRACELLULAR SPACES OF THE FABRICS AND MEDICAL PREPARATION TO CARRY OUT SUCH PROCEDURE.
JP2016505050A5 (en)
RU2021119487A (en) Combination drug with antiviral effect for the prevention of infection with SARS-CoV-2
CN119700755B (en) Application of compounds in the preparation of drugs for the prevention and/or treatment of altitude sickness
WO2021022058A3 (en) Antiarrhythmic formulation
CN108472375A (en) The therapy of middle severe influenza
RU2022101386A (en) The use of a drug having an antiviral effect for the prevention or treatment of SARS-CoV-2 coronavirus infection (variants) and a method for the prevention or treatment of SARS-CoV-2 (infection)
US20230233488A1 (en) Novel use of a modulator of glucosylceramide degradation for viral infections
RU2002120894A (en) A method for the treatment of post-inflammatory bullous keratopathy
RU2013141926A (en) THERAPEUTIC APPLICATION OF DIMIRACETAM FOR PREVENTION OF A PALM SUSPENSION SYNDROME CAUSED BY SORAFENIB
JP2006508993A5 (en)
Serghini et al. Fatal intoxication caused by the application of the multiple transdermals patchs of fentanyl
UA144734U (en) METHOD OF TREATMENT OF VIRAL INFECTIOUS DISEASES
US11364218B2 (en) Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome
IT202000008917A1 (en) ANTIVIRAL COMPOSITIONS
EA201590323A1 (en) METHOD OF INTRODUCTION OF ACTIVE SUBSTANCES IN THE HEAD BRAIN
WO2024097415A1 (en) Tumescent solution with b vitamins